Drug Abuse News and Research

RSS

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

Gene mutation can lead to different mental illnesses when influenced by same environmental factor

Male mice born with a genetic mutation that's believed to make humans more susceptible to schizophrenia develop behaviors that mimic other major psychiatric illnesses when their mothers are exposed to an assault to the immune system while pregnant, according to new Johns Hopkins research.

4 Dec 2010

Quitting smoking eases symptoms of depression

Quitting smoking is certainly healthy for the body, but doctors and scientists haven't been sure whether quitting makes people happier, especially since conventional wisdom says many smokers use cigarettes to ease anxiety and depression. In a new study, researchers tracked the symptoms of depression in people who were trying to quit and found that they were never happier than when they were being successful, for however long that was.

3 Dec 2010

Willpower can be learned

Good things come to those who wait. A scientist who showed that willpower can be learned–and that it carries lifelong benefits–has won the 2011 University of Louisville Grawemeyer Award for Psychology.

1 Dec 2010

Léger Marketing survey shows substance abuse problems are major concern for Quebecers

More than one in eight Quebecers think drug and alcohol dependency problems are public health issues of concern. In the Léger Marketing survey "Quebecers and Substance Abuse," released today as part of Drug Awareness Week, half of respondents say they are affected by substance abuse problems among those around them.

26 Nov 2010

Fake pot now illegal

The U.S. Drug Enforcement Administration (DEA) had to resort to its emergency powers this Wednesday to ban K2 and other “fake pot” products that mimic the effects of marijuana. As of now it is illegal to possess or sell the five chemicals used to make the products for at least one year. The agency and the Department of Health and Human Services will further debate whether the chemicals should be permanently added to the federal list of controlled substances considered unsafe, highly abused and without medical use.

24 Nov 2010

CCSA releases Portfolio of Canadian Standards for Youth Substance Abuse Prevention

Schools, families and community practitioners now have a practical prevention resource guide to help prevent and stop youth from using drugs.

23 Nov 2010

Researchers highlight importance of motivating people to seek HIV testing

HIV infected patients whose treatment is delayed not only become sicker than those treated earlier, but also require tens of thousands of dollars more in care over the first several years of their treatment.

23 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

38kg of illicit drugs seized before Schoolies Week

In a series of drug busts nearly 38 kilograms of illegal drugs were recovered in Queensland ahead of Schoolies Week celebrations. The drugs were seized by the Australian Federal Police (AFP) and Australian Customs and Border Protection.

18 Nov 2010

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Titan Pharmaceuticals, Inc. today announced that data from its Phase 3 clinical development program for Probuphine were presented at the Society for Neuroscience Annual Meeting, being held Nov. 13-17 in San Diego.

18 Nov 2010

Studies explore lifestyle's influence on wellness and brain health

New research is providing a deeper understanding of how individual actions - such as exercising, sensory stimulation, or drinking - influence brain health and outcomes. This new knowledge could ultimately lead to interventions in age-related cognitive declines, drug abuse, stroke, and brain injury, separate from or in combination with traditional pharmacological approaches. These findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

Teen brain responds differently to drugs than adult

New research released today shows teenagers respond differently to drugs than adults and explores the long-lasting effects of drug use on brain development. One study shows people who start using drugs at a young age have greater cognitive shortfalls, including mental flexibility. Animal studies also suggest adolescents are more susceptible to lower doses of cocaine, are willing to work more for a cocaine "fix" than adults, and are at risk of developing compromised stress responses.

17 Nov 2010

Young marijuana users suffer most cognitive damage: Study

Many marijuana smokers begin early. A new study shows that these people did much worse on tests of executive brain function than those who started smoking when they were older. Researchers highlight the danger posed by marijuana and the need to develop effective strategies to reduce marijuana use, especially among young people in their study.

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Titan third quarter net loss decreases to $0.4 million

Titan Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Best ways for proper disposal of unused medicines

Patients in cities all over the country will learn tomorrow about one of the best ways to avoid today's rampant prescription drug abuse – proper disposal of unused medicines.

15 Nov 2010

Alcohol consumption among young Spaniards linked to night-time violence

Night-time violence among young Spaniards is becoming ever more common, according to a research study carried out by the European Institute of Studies on Prevention. The study shows that 5.2% of young people carry weapons when they go out at night, 11.6% have been attacked or threatened, and 23% have got into a fight at some time.

12 Nov 2010

Trimega Laboratories achieves Investors in People accreditation

UK based Trimega Laboratories is pleased to announce that it has been recognized as having met the standards set by the prestigious Investors in People (IIP) Standard.

12 Nov 2010